Introduction Interleukin (IL)-18 is a key modulator of the cytokine response that leads to organ dysfunction and prolonged intensive care unit (ICU) stay after cardiopulmonary bypass surgery. We hypothesised that variation in the proinflammatory gene IL-18 is associated with adverse clinical outcome because of a more intense inflammatory response.
Introduction
The balance of pro-inflammatory (e.g. tumour necrosis factor alpha (TNF-α)) and anti-inflammatory (e.g. interleukin (IL)-10) cytokine gene expression is highly correlated with organ dysfunction and adverse outcome after cardiopulmonary bypass (CPB) surgery [1] . IL-18 is a key cytokine regulator of this balance that, among other clinical and cytokine measures, stands out as predictive of organ dysfunction and adverse outcomes after CPB [2] . IL-18 acts with IL-12 in a synergistic fashion to stimulate the release of interferon-gamma (IFN-γ) from lymphocytes [3] . High serum levels of IL-18 are associated with increased production of the pro-inflammatory cytokine TNF-α [4] and decreased production of the anti-inflammatory cytokine IL-10 [5] . Serum levels of IL-18 increase in response to CPB surgery [2] and in other inflammatory conditions such as sepsis [6] and type 1 diabetes [7] .
Inflammatory gene polymorphisms have been linked to the intensity of the post-operative inflammatory response and to clinical outcomes after CPB surgery [8] . Therefore, we postulated that IL-18 gene single nucleotide polymorphisms (SNPs) may be important in recovery from CPB surgery. Two polymorphic loci within the IL-18 gene have been investigated for associations between genotype and serum concentrations of IL-18 (intermediate phenotype) as well as associations between genotype and clinical outcome (phenotype). The -BMI: body mass index; bp: base pair; CI: cardiac index; CPB: cardiopulmonary bypass; CVP: central venous pressure; ELISA: enzyme-linked immunosorbent assay; htSNP: haplotype tag single nucleotide polymorphism; ICU: intensive care unit; IL: interleukin; INF-γ: interferon-gamma; MAP: mean arterial pressure; PCR: polymerase chain reaction; SE: standard error; SIRS: Systemic Inflammatory Response Syndrome; SNP: single nucleotide polymorphism; SVRI: Systemic Vascular Resistance Index; TNF-α: Tumour necrosis factor-alpha 607 C/A and -137 G/C SNPs were initially discovered to influence promoter activity of the IL-18 gene [9] . The -137 C allele has been associated with adverse outcomes and higher serum IL-18 cytokine levels, and the -607 A allele has been associated with improved outcomes and lower serum IL-18 levels in type 1 diabetes [3] .
Our study design was based on the above observation that increased serum IL-18 is associated with adverse outcomes after CPB, including cardiovascular dysfunction [2] , associated with increased serum TNF-α and decreased serum IL-10 [10] . Therefore, we tested the hypothesis that IL-18 gene polymorphisms are associated with adverse outcome, as measured by prolonged stays in the intensive care unit (ICU) (primary clinical outcome) and cardiovascular dysfunction (secondary clinical outcome). We then confirmed that the polymorphism is associated with increased serum concentrations of IL-18 and altered serum concentrations of TNF-α and IL-10 post-CPB, thus providing a possible explanation for our clinical results.
Materials and methods

Patient cohort
All patients admitted to the cardiac surgery ICU of St Paul's Hospital in Vancouver having elective CPB surgery between February 2001 and December 2003 were eligible for entry into this study. For inclusion, 890 were screened, of which 815 had CPB pump-driven circulation of blood during firsttime elective coronary artery bypass surgery. Of these, we restricted our analyses to the 658 patients who were Caucasian in order to decrease the potentially confounding influence of population admixture secondary to ethnic diversity on associations between genotype and phenotype. All 658 patients were successfully genotyped for four polymorphisms in the IL-18 gene and made up our final cohort for analysis.
Our Research Ethics Board approved analysis of fully anonymous data and, for DNA samples, collection of blood that was being discarded as part of routine clinical care in a consecutive cohort of all patients meeting inclusion criteria and admitted to our cardiac surgical ICU. Using this fully anonymous study design the Research Ethics Board of Providence Health Care and the University of British Columbia approved this study and waived informed consent.
Primary clinical phenotype
This cohort was confined to patients undergoing first-time elective coronary artery bypass surgery, so a mortality rate endpoint would be ineffective unless sample sizes were very large. Many authors, therefore, use prolonged ICU stay as a measure of adverse outcome [11, 12] . Most recently, Nakasuji and colleagues found that prolonged ICU stay of more than three days was a sensitive and specific measure of adverse outcome that reflected measures of cardiovascular and pulmonary organ failure [11] . Lawrence and colleagues found that the Parsonnet score with a maximum predictive efficiency was a score of 10. Patients having a Parsonnet score of 0 to 9 had a mean ICU stay of about 1.5 days, while those having a score of 10 or more had a mean ICU stay of about three days [12] . Therefore, we used the proportion of patient having a postoperative ICU stay of greater than or equal to three days (72 hours) as our primary outcome variable. In our institution, the decision to discharge patients from the ICU after CPB surgery is protocol driven and genotype was unknown to care providers, making this measurement an unbiased outcome measurement for this study, particularly because genotype was fully blinded and not measured until after complete clinical data had been collected.
Secondary clinical phenotype
Kristof and Magder [13] identified low post-CPB systemic vascular resistance index (SVRI) as a clinical manifestation of systemic inflammation. This vasodilatory syndrome is associated with related parameters such as longer cross-clamp times and lower post-CPB platelet count [13] . We used Kristof and Magder's definition of two consecutive SVRI measurements less than 1800 dyne.s/cm 5 /m 2 (SVRI = ((MAP-CVP) × 80)/CI, where MAP is the mean arterial pressure, CVP is the central venous pressure and CI is the cardiac index) as a secondary clinical phenotype.
Intermediate phenotype
Serum concentrations of cytokines are useful intermediate phenotypes to test for biologically plausible explanations for genotype -clinical phenotype associations. We measured serum IL-18, TNF-α and IL-10 concentrations in an overlapping subset of patients (n = 44) within the current cohort for whom serum was available from a related observational study. Inclusion and exclusion criteria for this cohort were identical. In our own preliminary time course experiments we found that serum IL-18 concentrations peaked at 24 hours post-CPB. Therefore, we measured serum IL-18, TNF-α and IL-10 at this post-operative time point. Serum IL-18 and TNF-α were measured by ELISA (R&D Systems, Minneapolis, MN for IL-18; BD PharMingen, San Diego, CA for TNF-α). Serum IL-10 was measured using the Luminex bead-based bioassay system (Luminex Corp, Austin, TX).
Tag single nucleotide polymorphism selection
To determine IL-18 gene haplotypes we used unphased genotype data from the University of Arizona's Innate Immunity Program in Genomics Application website. We used PHASE v 2.0 [14] to infer haplotype from unphased genotype data. The resulting haplotypes were clustered into four groups of similar haplotypes (clades) using the molecular evolutionary genetic analysis software package MEGA2 [15] . The program LDSelect [16] was used to select a set of maximally informative haplotype tag (ht) SNPs with the restriction that the literature SNPs -607 C/A and -137 G/C be included. Four htSNPs were chosen to differentiate the four haplotype clades: -607 C/A (rs1946518), -137 G/C (rs187238), 8148 C/T (rs360722) and 9545 T/G (rs5744249) (Figure 1 ).
Genotyping
DNA was extracted from peripheral blood samples using a QIAamp DNA Blood Maxi Kit (Qiagen Inc. Canada, Mississauga, ON, Canada). SNP genotypes were determined using the 5' nuclease, or Taqman PCR method (Applied Biosystems; Foster City, CA, USA) [17] . These htSNPs were then genotyped in the 658 patients of our cohort undergoing CPB.
Statistics
Differences in continuous variables were assessed using Student's t-test for two groups or an analysis of variance for more than two groups for normally distributed data, and a MannWhitney U Test or Kruskal-Wallis H Test for non-normally distributed data. Fisher's exact test was used to test for significant differences in discrete variables. Data are reported as mean ± standard error (SE). A p ≤ 0.05 was taken to indicate a significant difference. Analysis was performed using SPSS v11.5 (SPSS, Chicago, IL, USA). Allele frequencies were tested for Hardy-Weinberg equilibrium using the test of Guo and Thompson [18] and were all found to be in Hardy-Weinberg equilibrium.
Work by Long and Langley [19] indicates that on the order of 500 individuals are sufficient to detect the presence of causative polymorphisms having small effect on outcomes. Thus, we have included 658 individuals in our study population.
Results
Selection of the 9545 T/G SNP
Using PHASE, we found four main haplotypes occurring at a frequency greater than 5% in our patient cohort based on the four chosen htSNPs (Figure 1b) . As an initial screen, we examined the occurrence of our primary clinical outcome (prolonged ICU stay) by PHASE-inferred haplotype in our study cohort. We found haplotypes 1 to 3 were associated with greater occurrence of prolonged ICU stay ( Figure 2 ). Haplotypes 1 to 3 are uniquely tagged by the T allele of the 9545 T/ G polymorphism, so we focused on the 9545 T/G genotype for further analyses. These data were best fit using a recessive model (TT genotype compared to TG plus GG genotypes), which was therefore used as the statistical analytic model throughout the study. The TT genotype occurred in 58% of patients. Genotypes of the 9545 T/G SNP were in Hardy Weinberg equilibrium. No significant associations between genotype and any clinical or intermediate phenotype were observed for any of the three other htSNPs (data not shown).
Baseline and peri-operative characteristics
There were no significant differences between patients homozygous for the T allele of the IL-18 9545 T/G SNP versus patients having a GT or GG genotype in baseline characteristics (Table 1 ) except for body mass index (BMI) (28 kg/m 2 for patients with TT genotype, 28 kg/m 2 for patients with GT genotype, 26 kg/m 2 for patients with GG genotype, p = 0.022). There were no significant differences by genotype in peri-operative management, including use of aprotinin (TT 15%, GT+GG 10%, p = 0.10), amicar (TT 39%, GT+GG 38%, p = 0.99), or protamine (TT 0%, GT+GG 1%, p = 0.18) in our study cohort. Similarly, there were no differences by genotype in the use of vasodilators dobutamine (TT 71%, GT+GG 75%, p = 0.25) or milrinone (TT 11%, GT+GG 13%, p = 0.47) in the perioperative period. In addition there was no difference in vasopressor use (receiving norepinephrine at 4, 12 and 24 hours: TT 7.8%, 5.2%, 2.1%, GT+GG 7.2%, 5.4%, 1.1%, respectively).
Primary clinical phenotype
In our cohort of Caucasian patients who had CPB surgery, patients homozygous for the T allele of the IL-18 9545 T/G SNP had increased occurrence of prolonged ICU stay (greater than 72 hours) after CPB surgery: 32 of 383 (8.4%) for TT versus 10 of 275 (3.6%) for TG or GG (p = 0.015; Figure 3) . The overall occurrence of prolonged ICU stay was 42 out of 658 patients (6.4%). These differences remained significant (p = 0.012) using logistic regression adjusted for age, gender, duration of bypass and baseline organ function (ejection fraction, diabetes, renal dysfunction; Table 2 ). The sensitivity of the TT genotype to predict prolonged ICU stay is (or true positive rate) 76% and the specificity (or true negative rate) is 43%.
Secondary clinical phenotype
In these Caucasian patients undergoing elective on-pump coronary bypass graft surgery (CPB), those patients homozygous for the T allele of the IL-18 9545 T/G SNP had increased frequency of two consecutive SVRI measurements less than 1800 dyne.s/cm 5 /m 2 . The TT genotype was associated with the increased frequency of two SVRI measurements less than 1800 (62%) compared with the GT+GG genotypes (53%) (Figure 3 ). These differences remained significant (p = 0.045) using logistic regression adjusted for age, gender and duration of bypass (Table 3) . The difference in SVRI was not accounted for by differences in post-operative use of vasodilating inotropes or the vasopressor norepinephrine (above). The fraction of patients having two or more Systemic Inflammatory Response Syndrome (SIRS) criteria at 24 hours was 24% in TT patients and 20.7% in GT+GG patients. The heart rate component of SIRS scoring was significantly different with TT patients having a heart rate at 24 hours of 78.4 ± 0.7 compared with 75.8 ± 0.7 for GT+GG patients (p = 0.016). A trend to increased numbers of TT patients remaining on the ventilator at 24 hours (TT 10.2%, GT+GG 8.3%), increased numbers of patients having a rise in creatinine of more than 50 μmol/L at 24 hours (TT 4.1%, GT+GG 2.5%) and increased mortality (TT 1.8%, GT+GG 1.1%) was observed, although the numbers of patients falling into these categories was too low for these differences to be statistically significant.
Intermediate phenotype
In a subgroup of patients for whom serum cytokine measurements were available, a significant difference was found in the concentration of IL-18 24 hours post-CPB surgery by genotype of the IL-18 9545 T/G polymorphism. Patients homozygous for the T allele had a significantly greater mean serum IL-18 concentration (372 ± 24 pg/mL) compared with those with the GT or GG genotypes (260 ± 48 pg/mL, p = 0.018; Figure 4 (page number not for citation purposes)
Discussion
We have identified an association between the TT genotype of the novel 9545 T/G polymorphism of the IL-18 gene and adverse outcome after CPB surgery. The TT genotype was found to be associated with increased occurrence of prolonged ICU stay and of two consecutive SVRI measurements less than 1800 dyne.s/cm 5 /m 2 . A biologically plausible explanation for these findings is that the TT genotype of the 9545 T/G htSNP was also associated with higher serum concentration of IL-18, higher serum TNF-α concentration and lower serum concentration of IL-10 in our cardiac surgical population. Prolonged ICU stay is reported to be correlated with risk factors for poor outcome after CPB surgery [11] . Low systemic vascular resistance, defined as two consecutive SVRI measurements less that 1800 dyne.s/cm 5 /m 2 , is a marker of poor vascular tone after CPB, related to the systemic inflammatory response [13] . Greater serum concentrations of IL-18 [2] and TNF-α [1] and lower serum levels of IL-10 [1] have been associated with increased prevalence of complications after CPB, and may be indicative of a prominent pro-inflammatory state.
Production of humoral inflammatory mediators and priming of neutrophils by exposure to the CPB apparatus enables a 'post-pump' syndrome characterised by a systemic inflammatory response syndrome and its anti-inflammatory counterpart, termed the compensatory anti-inflammatory response syndrome [20] . IL-18 plays a central role in regulating and balancing these responses. IL-18 regulates the expression of the potent pro-and anti-inflammatory mediators TNF-α [4] and IL-10 [5] . In accord with this, we found that the TT genotype was associated with an increased serum IL-18 concentration and also with increased serum TNF-α and decreased serum IL-10. The increased serum TNF-α and decreased serum IL-10 levels are associated with increased organ dysfunction [10] . Therefore, our results are consistent with the hypothesis that the IL-18 9545 TT genotype leads to increased production of serum IL-18, subsequently leading to increased serum TNF-α and decreased serum IL-10, causing increased organ dysfunction and increased occurrence of prolonged ICU stay.
Polymorphisms in the IL-18 gene have been studied for association with inflammatory conditions such as type 1 diabetes [3] and sepsis [21] . The -607 C/A and -137 G/C promoter SNPs have been found to be associated with a susceptibility to type 1 diabetes such that the C allele of -137 was found to be a risk allele and the A allele of -607 was found to be a protective allele [3] . Polymorphisms in the IL-18 gene have also been associated with alterations in serum concentrations of IL-18 [22] . None of the previous literature reports an association between the 9545 T/G SNP and outcomes, or between this SNP and serum cytokine levels. The previous SNPs, -607 C/ A and -137 G/C are not in significant linkage disequilibrium with the 9545 T/G SNP ( Figure 1 ). Neither of these previously reported SNPs were in association with our primary or secondary clinical or intermediate phenotypes. [23] . The -2163 C/A SNP, however, is not found to be located within a putative transcription factor binding site, nor does the rare allele create one, based on a scan of the promoter region of the IL-18 gene using TESS (transcriptional element search software). Intronic SNPs can affect splicing of the pre-mRNA, resulting in alternative splice variants of proteins; however, most intronic SNPs thought to have these effects are observed to lie within about 20 bp of intron/exon boundaries [24] . Our study has several strengths. The use of haplotypes to choose htSNPs has the benefit of not being restricted to literature SNPs for disease association studies. The large sample size allows for statistical power to detect associations of modest effect and the limitation of sampling to Caucasians patients reduces the likelihood of type I error due to population admixture.
One of the main weaknesses of our study design is that we do not identify the causative SNP for worse clinical outcome after CPB. Linkage disequilibrium existing within and possibly beyond the IL-18 gene suggests that polymorphic loci in linkage disequilibrium with the T allele of the 9545 T/G SNP could contribute to detrimental effects after CPB surgery. We have limited our study to a single cohort; therefore this arising hypothesis should be tested in other cohorts to ensure reproducibility.
Conclusions
In the present study the TT genotype of a novel polymorphism of the IL-18 gene, 9545 T/G, was associated with greater occurrence of prolonged ICU stay after CPB surgery, greater frequency of low SVRI (two consecutive SVRI measurements < 1800 dyne.s/cm 5 /m 2 ), higher serum concentrations of cytokine IL-18, higher serum concentrations of the cytokine TNF-α and lower serum concentrations of the anti-inflammatory cytokine IL-10. These widely varied markers of intensity of recovery post-CPB indicate this genotype is potentially a risk factor for patients undergoing CPB surgery. 
